Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$49.38 - $63.75 $2.43 Million - $3.14 Million
-49,308 Reduced 44.53%
61,430 $3.82 Million
Q3 2023

Nov 14, 2023

SELL
$48.64 - $62.51 $2.55 Million - $3.27 Million
-52,347 Reduced 32.1%
110,738 $6.21 Million
Q2 2023

Aug 14, 2023

BUY
$47.99 - $60.21 $1.71 Million - $2.14 Million
35,573 Added 27.9%
163,085 $8.23 Million
Q1 2023

May 15, 2023

BUY
$52.6 - $67.34 $2.94 Million - $3.77 Million
55,969 Added 78.23%
127,512 $6.96 Million
Q4 2022

Feb 14, 2023

BUY
$59.56 - $76.6 $4.26 Million - $5.48 Million
71,543 New
71,543 $4.47 Million
Q2 2022

Aug 15, 2022

BUY
$39.5 - $64.42 $440,859 - $718,991
11,161 Added 28.71%
50,037 $2.84 Million
Q1 2022

May 16, 2022

BUY
$43.74 - $62.76 $886,915 - $1.27 Million
20,277 Added 109.02%
38,876 $2.43 Million
Q4 2021

Feb 14, 2022

BUY
$50.01 - $73.35 $930,135 - $1.36 Million
18,599 New
18,599 $1.04 Million
Q3 2021

Nov 15, 2021

SELL
$59.21 - $78.66 $558,883 - $742,471
-9,439 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$51.39 - $66.9 $256 - $334
-5 Reduced 0.05%
9,439 $599,000
Q1 2021

May 17, 2021

SELL
$49.14 - $59.89 $241,228 - $294,000
-4,909 Reduced 34.2%
9,444 $566,000
Q4 2020

Feb 12, 2021

BUY
$42.19 - $51.5 $605,553 - $739,179
14,353 New
14,353 $717,000
Q3 2020

Nov 16, 2020

SELL
$35.33 - $51.04 $280,131 - $404,696
-7,929 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$22.91 - $39.83 $29,668 - $51,579
-1,295 Reduced 14.04%
7,929 $278,000
Q1 2020

May 15, 2020

SELL
$16.44 - $37.73 $46,393 - $106,474
-2,822 Reduced 23.43%
9,224 $234,000
Q4 2019

Feb 14, 2020

SELL
$19.57 - $28.96 $124,602 - $184,388
-6,367 Reduced 34.58%
12,046 $334,000
Q3 2019

Nov 14, 2019

BUY
$26.92 - $42.41 $495,677 - $780,895
18,413 New
18,413 $496,000

Others Institutions Holding AXNX

About Axonics, Inc.


  • Ticker AXNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 49,123,600
  • Market Cap $3.49B
  • Description
  • Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...
More about AXNX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.